3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 3
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Hepatocellular
21
Parkinson Disease 4, Autosomal Dominant Lewy Body
15
Carcinoma, Renal Cell
7
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Squamous Cell Carcinoma of Head and Neck
2
Melanoma
2
von Hippel-Lindau Disease
1
Thyroid Neoplasms
1
Recurrence
1
Neoplasms
1
Neoplasm Metastasis
1
Liver Neoplasms
1
Kidney Neoplasms
1
Hematologic Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Differentiated Thyroid Cancer (DTC)
1
Colorectal Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Advanced Malignancies
1
Advanced Endometrial Cancer
1
Interventions
Gemcitabine
12
Mitomycin
11
Cisplatin
10
Carboplatin
8
pembrolizumab
7
Docetaxel
4
toripalimab
3
avelumab
3
atezolizumab
3
Paclitaxel
3
sacituzumab govitecan
2
disitamab vedotin
2
Taxes
2
Specimen Handling
2
Platinum
2
Magnetic Resonance Spectroscopy
2
Injections
2
1,2-diaminocyclohexaneplatinum II citrate
2
vinflunine
1
valrubicin
1
tislelizumab
1
lenvatinib
1
eribulin
1
epacadostat
1
enfortumab vedotin
1
durvalumab
1
dodecyl maltoside
1
Vitamin B 12
1
Standard of Care
1
Ramucirumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Carcinoma, Transitional Cell
×
lenvatinib
×
Clear all
NCT03898180
2026-02-05
LEAP-011
Merck Sharp & Dohme LLC
Phase 3
Completed
505 enrolled
19 charts